cas 916420-27-4|| where to buy tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

Product Name:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

IUPAC Name:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

Packing Unit	Available Stock	Price($)
CM104183-5g	in stock	ŌǸ
CM104183-10g	in stock	ƴĳƴ
CM104183-25g	in stock	ħƚħ
CM104183-100g	in stock	ǙŮƈ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 916420-27-4 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:916420-27-4; Molecular Formula:C12H15Cl2N3O2; Melting Point:-; Smiles Code:CC(C)(C)OC(=O)N1CCC2=C(Cl)N=C(Cl)N=C2C1; Density:

: Catalog Number:CM104183; Molecular Weight:304.17; Boiling Point:; MDL No:MFCD09025732; Storage:

: Adagrasib; Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.